Radius Health Inc
NASDAQ:RDUS

Watchlist Manager
Radius Health Inc Logo
Radius Health Inc
NASDAQ:RDUS
Watchlist
Price: 30 USD Market Closed
Market Cap: 847.8m USD

Radius Health Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Radius Health Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Radius Health Inc
NASDAQ:RDUS
Free Cash Flow
-$28.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$19.7B
CAGR 3-Years
-4%
CAGR 5-Years
5%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$9.7B
CAGR 3-Years
2%
CAGR 5-Years
3%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$13.1B
CAGR 3-Years
13%
CAGR 5-Years
5%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
-4%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.9B
CAGR 3-Years
-2%
CAGR 5-Years
20%
CAGR 10-Years
20%
No Stocks Found

Radius Health Inc
Glance View

Market Cap
847.7m USD
Industry
Biotechnology

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company is headquartered in Boston, Massachusetts and currently employs 293 full-time employees. The company went IPO on 2014-06-06. The firm is focused on developing and commercializing endocrine therapeutics. Its lead product, TYMLOS (abaloparatide) injection, is a prescription medicine for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The firm also has products in clinical pipeline, which includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in the treatment of postmenopausal women with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group, and RAD011, a synthetic cannabidiol oral solution that is being developed for the treatment of Prader-Willi syndrome (PWS).

RDUS Intrinsic Value
76.48 USD
Undervaluation 61%
Intrinsic Value
Price

See Also

What is Radius Health Inc's Free Cash Flow?
Free Cash Flow
-28.6m USD

Based on the financial report for May 31, 2025, Radius Health Inc's Free Cash Flow amounts to -28.6m USD.

What is Radius Health Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
-322%

Over the last year, the Free Cash Flow growth was -322%.

Back to Top